Stock Information
Halozyme Therapeutics Inc (HALO)
Ticker Symbol: HALO
Exchange: NASDAQ
Sector: Biotechnology
Market Cap: $7,583.83 mil
Piotroski score: 5
PE Ratio: 25.1725
EPS (TTM): 2.4916
Revenue (TTM): $11.87 M
Dividend Yield: N/A%
ROE: 92.67%
Latest News
-
Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock?
Wed, Apr 15, 2026 10:17 AM
-
Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series ("ETF Series") and Exchange Traded Funds ("ETFs")
Tue, Apr 14, 2026 8:00 PM
-
3 Cash-Producing Stocks with Exciting Potential
Fri, Apr 10, 2026 8:06 PM
-
Did Halozyme’s Vertex Hypercon Licensing Deal Just Shift Halozyme Therapeutics’ (HALO) Investment Narrative?
Fri, Apr 10, 2026 6:12 PM
-
2 Small-Cap Stocks with Solid Fundamentals and 1 We Ignore
Thu, Apr 9, 2026 1:25 PM
-
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Thu, Apr 9, 2026 1:00 PM
-
Halozyme and Vertex sign deal for Hypercon technology
Wed, Apr 8, 2026 9:32 AM
-
1 Small-Cap Stock for Long-Term Investors and 2 We Brush Off
Wed, Apr 8, 2026 9:25 AM
Key Financials
Financial data not available
